Rothschild Capital Partners LLC Buys New Shares in Stryker Co. (NYSE:SYK)

Rothschild Capital Partners LLC acquired a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 820 shares of the medical technology company's stock, valued at approximately $295,000.

A number of other hedge funds have also made changes to their positions in the stock. Stonebridge Capital Advisors LLC boosted its holdings in Stryker by 2.0% during the fourth quarter. Stonebridge Capital Advisors LLC now owns 7,695 shares of the medical technology company's stock worth $2,771,000 after buying an additional 149 shares in the last quarter. Voya Investment Management LLC boosted its stake in Stryker by 79.2% in the 4th quarter. Voya Investment Management LLC now owns 706,724 shares of the medical technology company's stock worth $254,412,000 after purchasing an additional 312,434 shares during the period. Integrated Wealth Concepts LLC boosted its stake in Stryker by 10.9% in the 4th quarter. Integrated Wealth Concepts LLC now owns 6,240 shares of the medical technology company's stock worth $2,247,000 after purchasing an additional 611 shares during the period. Burling Wealth Partners LLC acquired a new position in Stryker in the 4th quarter worth approximately $1,933,000. Finally, Sompo Asset Management Co. Ltd. boosted its stake in Stryker by 1.7% in the 4th quarter. Sompo Asset Management Co. Ltd. now owns 2,360 shares of the medical technology company's stock worth $850,000 after purchasing an additional 40 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of Stryker stock traded up $4.43 during midday trading on Tuesday, hitting $370.92. 1,104,111 shares of the company were exchanged, compared to its average volume of 1,355,517. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $141.58 billion, a P/E ratio of 47.80, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a 50 day simple moving average of $367.37 and a 200-day simple moving average of $373.51.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business posted $3.46 earnings per share. Research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. Stryker's payout ratio is presently 43.30%.

Analysts Set New Price Targets

Several analysts recently issued reports on SYK shares. Wells Fargo & Company increased their price objective on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Citigroup reissued a "buy" rating and set a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Canaccord Genuity Group increased their price objective on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, Stifel Nicolaus increased their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $423.53.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.